Science lead on Selumetinib (MEK
inhibitor) and AZD4547 (FGFR tyrosine kinase inhibitor)
• Bioscience representative on the licensing team
so responsible for evaluating licensing/partnering
opportunities for drug projects from academia/biotech
and peer pharma
• Co-lead the target selection team so interested in new drug
targets regardless of area of cancer biology
• Project lead for an early stage drug discovery
project targeting the immune-suppressive tumour
microenvironment
• Scientific interests: RAS_MAPK signalling, mutRAS
cancers in general, lung cancer specifically, impact of
tumour biology on the anti-tumour immune responses